Differences in clinical features between axial psoriatic arthritis and axial spondyloarthritis: a systematic review and meta-analysis of observational studies - Takeaways - MDSpire

Differences in clinical features between axial psoriatic arthritis and axial spondyloarthritis: a systematic review and meta-analysis of observational studies

  • By

  • Zhihao Qiu

  • Zijie Chen

  • Zhe Yang

  • Ruibo Xia

  • Weikai Chen

  • Yuwei Zhu

  • Weijie Wang

  • Zhengfu Li

  • Kepeng Yang

  • June 22, 2026

  • 0 min

Share

  • 1

    This systematic review and meta-analysis compared clinical features of axial psoriatic arthritis (ax-PsA) and axial spondyloarthritis (ax-SpA).

  • 2

    Fifteen studies involving 2,704 patients with ax-PsA and 9,248 with ax-SpA were analyzed for disease activity, spinal function, inflammatory markers, and HLA-B27 positivity.

  • 3

    Meta-analysis revealed no significant differences in disease activity scores or functional indices between ax-PsA and ax-SpA.

  • 4

    Ax-PsA showed significantly lower HLA-B27 positivity compared to ax-SpA, with a risk ratio of 0.37 (95% CI, 0.32–0.43; p < 0.001).

  • 5

    The findings support the distinction of ax-PsA and ax-SpA as separate entities, highlighting the need for HLA-B27 testing in clinical differentiation.

Original Source(s)

Differences in clinical features between axial psoriatic arthritis and axial spondyloarthritis: a systematic review and meta-analysis of observational studies

  • by Zhihao Qiu, Zijie Chen, Zhe Yang, Ruibo Xia, Weikai Chen, Yuwei Zhu, Weijie Wang, Zhengfu Li, Kepeng Yang

  • June 22, 2026

Related Content

Psoriatic Arthritis Linked to Rare Vocal Issue

Bilateral vocal cord immobility linked to cricoarytenoid joint fixation highlights diagnostic consideration for unexplained airway symptoms.

Combo Therapy for Psoriasis With Obesity

A phase 3b trial tests ixekizumab plus tirzepatide in adults with moderate-to-severe plaque psoriasis and obesity or overweight.

Evaluation of serum TWEAK levels and treatment response in psoriasis and psoriatic arthritis: a prospective comparative case–control study of adalimumab and methotrexate